Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer)

New England Journal of Medicine

October 8, 2016

10.1056/nejmoa1611299

Cited by 1,309

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

|New England Journal of Medicine|2011|7.7k

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

|New England Journal of Medicine|2018|1.8k

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

|New England Journal of Medicine|2017|1.4k

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

|The Lancet Oncology|2014|978

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

|The Lancet|2008|642